White Paper: Specialty Drugs in Workers' Compensation: A Population Based Assessment

White Paper: Specialty Drugs in Workers' Compensation: A Population Based Assessment

Specialty drugs represent the fastest growing category of drugs in the United States and projections indicate that they will account for half of all drug costs in less than five years. In general terms specialty drugs are defined as very expensive drugs that are designed to treat relatively rare conditions. Although prevailing opinion has indicated that many of these conditions, such as multiple sclerosis and hemophilia, will have little impact on drug spending, in workers’ compensation, myMatrixx identifies seven significant patient populations in this white paper in which specialty drugs are the treatment of choice and will most likely be deemed compensable. Read more in our in-depth report.

 

Download